HK-listed biopharmaceutical group Antengene rises in Hong Kong debut

Antengene

20/11/2020 03:05

** Shares of oncology medicine-focused biopharmaceutical
firm Antengene Corp Ltd  6996.HK  trade as high as HK$19.68 per
share in Hong Kong debut, up 8.8% from the IPO price of HK$18.08
apiece
    ** Stock ranks seventh most actively traded shares by
turnover  
    ** Shanghai-based Antengene offered 154.15 mln shares in
Hong Kong IPO, raising HK$2.79 bln ($359.8 mln) for development
of core products in oncology therapies, and for expanding
pipeline of new drug candidates  urn:newsml:reuters.com:*:nFWN2I410I
    ** The Hang Seng China enterprises index  .HSCE  edges down
0.1%, while the benchmark index  .HSI  gains 0.3%
   ($1 = 7.7534 Hong Kong dollars)

 (Reuters Messaging: donny.kwok.thomsonreuters.com@reuters.net)